Coronary Artery Disease
Conditions
Interventions
Additional treatment of Teneligliptin
Conventional treatment
Sponsors
Kameda Medhical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Elective PCI patients 2)Patients who have T2DM and HbA1c (NGSP) level are more than 7% before PCI 3)Patients aged 30 up to 80 years old 4)Informed consent was signed by all patients and documented.
Exclusion criteria
Exclusion criteria: 1)Patients with T1DM (type 1 diabetes mellitus) 2)Patients who have medical history of hypersensitivity to diabetes mellitus drugs 3)Patients with medical history of malignant tumor 4)Patients with severe infection, before and after operation, or severe trauma 5)Patients with cardiac arrest (class of III in NYHA) 6)Patients with uncontrolled hypertension 7)Patients with insulin dependent and the potential to change diabetic drugs 8)Patients with severe renal insufficiency (eGFR is less than 30 mL / min / 1.73 m2, dialysis-dependent, or serum creatinine (men, more than 2.5 mg / dL, women, more than 2.0 mg / dL 9) Patients with pregnant, and possibly pregnant 10) Patients with severe ketosis, diabetic coma, or history of coma within the past six months 11)Patients who had stroke, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemic attack within the past three months. 12)Patients who enrolled into another clinical test within three months prior to this trial 13)Patients who cannot administer antiplatelet drugs 14)Patients who were considered as inappropriate for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variation amount and rate of inflammatory markers from pretreatment levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vascular endothelial function: RH-PAT score, variation amount and rate of HbA1c, and glucose from pretreatment levels. | — |
Countries
Japan
Contacts
Public ContactAya JUNI
AsMediX Co., Ltd. GPO Department , Business Planning Section
Outcome results
None listed